Skip to main content

5 Questions with TMC Innovation Institute Director Tom Luby

Published Apr 15, 2019 by Maggie Martin

 

TMC Innovation Institute

 

Tom Luby was recently named director of the Texas Medical Center Innovation Institute. Luby previously headed up JLABS @ TMC.

Below, Luby shares his priorities, what he's looking forward to most this year and how the institute fits in with the rest of Houston's innovation ecosystem. 

What are your priorities as Director of the Texas Medical Center Innovation Institute?

The Texas Medical Center’s goal is to serve its 61 [institution] members, and everything we do stems from that. At the TMC Innovation Institute, we’re focused on attracting companies from around the globe and showing them the value of establishing a presence in the largest medical city in the world. We want to work with those companies, open doors for them and provide them with solutions that will meet their needs.

We are continuing to build upon the success of TMC Biodesign, our fellowship program that unites the talents of innovators in order to quickly bring breakthrough products to market. And, of course, we will continue to grow our signature TMCx accelerator program, which provides startup companies with shared workspace, a curriculum for entrepreneurs and access to more than 200 advisors. We've had more than 250 companies come through the Innovation Institute that have received more than $900 million in funding, so we’re doing well. But I’m eager to add even more fuel to that fire. 

We also want to engage with corporate partners and believe it’s critical that major health care companies establish significant footprints in Houston. Importantly, we’re also working to bring more startup capital to Houston, which is critical to fostering the success of early-stage companies in Houston. 

What are the projects and initiatives you’re excited for most this year? 

This summer, we will open TMCxi at our John P. McGovern Campus on Holcombe Boulevard. It will be nearly 25,000 square feet of Class A office space that provides a turnkey solution for industry partners who seek to establish a presence in our growing health care ecosystem.

We see TMCxi as an amazing resource for technology companies, venture capitalists and others who want to be in the heart of the Texas Medical Center. It’s an important part of the TMC Innovation Institute, and we’re eager to welcome our new partners here. 

Why is innovation in health care—and at the TMC—so important? 

It’s important that we always remember: it’s all about the patients. We have a growing population of older adults, and we all know that end-of-life health care tends to be the most expensive. We need solutions that will provide people with the opportunity to live longer, healthier, high-quality lives, and hopefully prevent them from becoming long-term patients. 

When we talk about innovation, we often talk about devices, but we’re also talking about other forms of innovation. We want to see innovation in the way that health care is packaged and delivered too. Health care is expensive, and it needs to be more efficient. We think innovation means addressing those challenges as well. 

How does your organization fit into Houston as a growing innovation hub?

The TMC Innovation Institute is on the leading edge of Houston’s growing health care startup ecosystem. Our job is to enable our members to more efficiently turn their work in basic science and translational research into new products that will ultimately help patients. It’s also to connect our members to the startups that are developing the tools they need to continue providing world-class, cutting-edge health care. Additionally, our role is to recruit health care capital that can provide the crucial funding startups need to deliver on the promise of innovation.

We are engaging with large health care companies and showing them the tremendous value of establishing a presence in a place that’s home to 9,000-plus patient beds and some of the top researchers and clinicians from around the world. Importantly, we recognize that top talent has the opportunity to work anywhere, so we continue to play a key role in recruiting the world’s best to the Texas Medical Center.

The TMC Innovation Institute’s vision is “to become the global leader in health and life science innovation.” How do you envision meeting that goal?

We’re going to continue pushing to grow and develop that startup ecosystem here. We’ll be working with our member institutions to do that, as well as other partners in the startup space here in Houston. There is so much momentum right now. I think it’s increasingly clear to the world that if you’re a health care startup, you really need to have a foothold in the Texas Medical Center.

I keep saying this, but that’s because it’s so important. A big part of accomplishing our goals will require more and more startup capital to invest in early-stage companies in Houston. We’re putting our money where our mouth is and investing $25 million in early-stage companies through the TMC Venture Fund. It’s our job to continue drawing the talent here, and to show the value of investing in our ecosystem. If you’re a venture capitalist or corporate partner interested in what’s happening in our health care startup ecosystem — come see us. 

Related News

Health Care

University of Houston, Baylor College of Medicine to Launch Cutting-Edge Research Hub

8/26/24
The University of Houston (UH) and Baylor College of Medicine (BCM) have been awarded a $44.2 million grant from the National Center for Advancing Translational Research. This funding will support the establishment of a regional hub dedicated to advancing clinical and translational research.  Dubbed the Consortium for Translational and Precision Health (CTPH), the new hub will enhance collaboration between the two institutions and other clinical and research groups within the Texas Medical Center. The CTPH aims to expedite the translation of new technologies and discoveries into patient care and real-world impact, provide funding and resources to accelerate pilot projects and research initiatives and connect investigators with local healthcare organizations and government agencies that are dedicated to healthcare, clinical research and policy.  “Research is the engine empowering health care’s life-changing advancements,” said UH President Renu Khator, in a release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”  The hub will be led by BCM’s Christopher Amos, professor and director of the Institute for Clinical and Translational Research, and Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology, alongside UH’s Dr. Bettina M. Beech, clinical professor of population health and chief population health officer.  “The CTPH is a partnership that draws on strengths of both institutions, creating a rich multidisciplinary environment. It will act as the vehicle to enhance the infrastructure and resources needed to effectively conduct research and implement solutions to advance healthcare,” said Dr. Carolyn Smith, interim senior vice president and dean of research at BCM. “It will help implement and create ongoing core research activities that will support the clinical translational science at both institutions.”  This strategic partnership comes at a time when local institutions are intensifying efforts to advance critical research that will deliver vital healthcare solutions. The University of Texas MD Anderson Cancer Center and Rice University recently announced a collaboration to advance fundamental and translational cancer research and develop life-saving technologies. Additionally, a research initiative led by Rice University, in collaboration with MD Anderson, received an $18 million grant to improve tumor removal technology for breast, head and neck cancer.  Learn more about Houston’s Life Sciences industry. 
Read More
Life Sciences

Rice University Awarded $18 Million to Advance Tumor Removal Technology

8/16/24
A research initiative led by Rice University, in collaboration with The University of Texas MD Anderson, has received an $18 million grant from the Advanced Research Projects Agency for Health (ARPA-H). The funding, which will be distributed over five years, will support the development of a new system aimed at enhancing the accuracy of tumor removal in breast, and head and neck cancer.   Rice University was among eight institutions chosen to receive a share of the $150 million in grants announced earlier this week by the Biden-Harris administration. This funding is part of the ongoing Cancer Moonshot initiative, which seeks to halve the cancer death rate by 2047.   The Rice and MD Anderson research team has developed a groundbreaking cancer pathology system called AccessPath, which addresses a significant challenge surgeons face: accurately identifying the margin where a tumor ends, and healthy tissue begins. Leveraging advanced technologies, including a high-resolution microscope and advanced artificial intelligence algorithms, AccessPath enables surgeons to determine in real time whether they have completely removed a tumor during surgery.  “Because of its low cost, high speed, and automated analysis, we believe AccessPath can revolutionize real-time surgical guidance, greatly expanding the range of hospitals able to provide accurate intraoperative tumor margin assessment and improving outcomes for all cancer surgery patients,” Rebecca Richards-Kortum, a lead researcher on the project and director of the Rice360 Institute for Global Health Technologies, said in a news release.  According to ARPA-H, nearly two million Americans are diagnosed with cancer each year. Given the complexity and high cost of cancer treatment, AccessPath offers a promising solution by “reducing the number of repeat interventions, lowering cancer care costs and improving patient outcomes,” said Dr. Ana Paula Refinetti, an associate professor in the Breast Surgical Oncology department at MD Anderson and one of the lead researchers on the project.  This cutting-edge innovation stems from a strategic partnership established this summer between Rice University and MD Anderson. Through the Cancer Bioengineering Collaborative, the two institutions are working together to develop life-saving technologies and bioengineering strategies to enhance cancer research, diagnosis and treatment.  “AccessPath is exactly the kind of life-changing research and health care innovation we are proud to produce at Rice, where we’re committed to addressing and solving the world’s most pressing medical issues,” said Ramamoorthy Ramesh, Rice’s executive vice president for research. “Partnering with MD Anderson on this vital work underscores the importance of such ongoing collaborations with our neighbors in the world’s largest medical center.”  This award is yet another example showcasing Houston’s leadership in advancing critical, life-saving technologies.  Learn more about Houston’s life sciences industry. 
Read More

Related Events

Economic Development

Life Sciences and Biotechnology Forum

Finding solutions to the problems that matter most is baked into Houston’s DNA. As the Third Coast for Life Sciences, the region’s world-class medical centers, research institutes and private companies are taking on…

Learn More
Learn More
Executive Partners